ICU Medical (ICUI) Scheduled to Post Earnings on Tuesday

ICU Medical (NASDAQ:ICUI - Get Free Report) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect ICU Medical to post earnings of $0.84 per share for the quarter. ICU Medical has set its FY24 guidance at $4.40-5.10 EPS and its FY 2024 guidance at 4.400-5.100 EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.39. The business had revenue of $587.86 million for the quarter, compared to analyst estimates of $564.77 million. ICU Medical had a negative net margin of 1.31% and a positive return on equity of 6.35%. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Up 0.5 %

NASDAQ ICUI traded up $0.52 on Tuesday, hitting $97.92. 161,794 shares of the company were exchanged, compared to its average volume of 248,351. The company has a market cap of $2.39 billion, a PE ratio of -79.61 and a beta of 0.69. ICU Medical has a 12 month low of $78.28 and a 12 month high of $212.43. The stock has a fifty day moving average of $101.40 and a 200-day moving average of $97.52. The company has a current ratio of 2.53, a quick ratio of 1.06 and a debt-to-equity ratio of 0.74.

Analyst Ratings Changes

Separately, KeyCorp increased their target price on shares of ICU Medical from $134.00 to $136.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $123.00.

Insiders Place Their Bets

In other ICU Medical news, VP Daniel Woolson sold 791 shares of the company's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $98.27, for a total transaction of $77,731.57. Following the transaction, the vice president now owns 13,980 shares in the company, valued at $1,373,814.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, COO Christian B. Voigtlander sold 13,603 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $107.19, for a total value of $1,458,105.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel Woolson sold 791 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $98.27, for a total transaction of $77,731.57. Following the completion of the sale, the vice president now owns 13,980 shares of the company's stock, valued at approximately $1,373,814.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,262 shares of company stock worth $2,545,532. Insiders own 6.70% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.